Kaci Fatma Necmiye, Daglioglu Cenk
University of Leeds, Faculty of Medicine and Health, St. James's University Hospital, Leeds, UK.
Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Medical Biochemistry, Fatih/Istanbul, Turkey.
Cell Biochem Biophys. 2025 Jun 30. doi: 10.1007/s12013-025-01813-3.
Resistance to chemotherapy remains a major obstacle in effective cancer treatment. To address this challenge, we developed multifunctional FeO@SiO(FITC)-BTN/FA/3AB nanoparticles aimed at selectively enhancing the therapeutic efficacy of 3-aminobenzamide (3AB) while minimizing systemic toxicity, particularly when combined with low-dose cisplatin chemotherapy. In this study, we demonstrate that these nanoparticles not only exhibit potent cytotoxic effects against lung adenocarcinoma cells but also show significant therapeutic potential in human cervical adenocarcinoma models. We systematically evaluated their performance through cellular uptake assay, viability assay, apoptosis analysis, single-cell colony formation assay, mitochondrial membrane potential (MMP) assay, and quantitative PCR (qPCR). Our findings reveal that the nanoparticle formulation efficiently facilitates the intracellular delivery of 3AB, leading to robust inhibition of tumor cell proliferation and migration. Overall, the FeO@SiO(FITC)-BTN/FA/3AB nanoparticle system represents a promising platform for intratumoral therapy, offering a targeted strategy to potentiate the efficacy of PARP1 inhibition in DNA repair for cervical cancer treatment.
对化疗的耐药性仍然是有效癌症治疗中的一个主要障碍。为应对这一挑战，我们开发了多功能FeO@SiO(FITC)-BTN/FA/3AB纳米颗粒，旨在选择性地提高3-氨基苯甲酰胺（3AB）的治疗效果，同时将全身毒性降至最低，特别是在与低剂量顺铂化疗联合使用时。在本研究中，我们证明这些纳米颗粒不仅对肺腺癌细胞表现出强大的细胞毒性作用，而且在人宫颈腺癌模型中也显示出显著的治疗潜力。我们通过细胞摄取试验、活力试验、凋亡分析、单细胞集落形成试验、线粒体膜电位（MMP）试验和定量PCR（qPCR）系统地评估了它们的性能。我们的研究结果表明，纳米颗粒制剂有效地促进了3AB的细胞内递送，从而强烈抑制肿瘤细胞的增殖和迁移。总体而言，FeO@SiO(FITC)-BTN/FA/3AB纳米颗粒系统代表了一种有前景的肿瘤内治疗平台，为增强PARP1抑制在宫颈癌治疗中的DNA修复疗效提供了一种靶向策略。
